Anavex Life Scie SEC Filings

Anavex Life Sciences Corp. (AVXL) reported that it has released its financial results for the fiscal year ended September 30, 2025. The company filed a Form 8-K to announce that these results are presented in a separate press release dated November 25, 2025, which is attached as Exhibit 99.1. The 8-K specifies that the results and the exhibit are being furnished under Item 2.02, meaning they are not treated as filed for certain liability purposes unless expressly incorporated into future reports.

Anavex Life Sciences reported a regulatory setback: the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote following the oral explanation for the Marketing Authorization Application (MAA) of blarcamesine.

The company plans to request a re-examination once the CHMP opinion is formally adopted and to provide additional biomarker data in line with feedback from CHMP, EMA, and the Alzheimer’s disease community. A press release with further details was provided as Exhibit 99.1.

Sandra Boenisch, the PFO & Treasurer of Anavex Life Sciences Corp. (AVXL), reported a change in beneficial ownership on 10/02/2025. A derivative transaction shows acquisition of 12,500 shares underlying a stock option at an exercise price of $5.36. After the transaction, the filing reports 25,000 shares beneficially owned directly by Ms. Boenisch. The filing explains the option was originally granted on 02/20/2024 for 50,000 shares and vests in four equal tranches tied to performance milestones; one milestone (readout of the AV3-71-SZ-001 schizophrenia study) was met, causing vesting of the 12,500 tranche.

Anavex Life Sciences (AVXL) disclosed that President and CEO Christopher Missling had 125,000 stock options vest on 10/02/2025. The options carry an exercise price of $5.36 and expire on 02/20/2034.

These options are part of a 500,000-share grant made on 02/20/2024 that vests in four equal tranches tied to performance milestones, including the readout of the AV3-71-SZ-001 schizophrenia study, which was met, triggering this vesting tranche.

Following the reported transaction, 250,000 derivative securities were beneficially owned.

Sandra Boenisch, Chief Financial Officer and Treasurer of Anavex Life Sciences Corp. (AVXL), reported the vesting and exercise of a portion of a previously granted option. A stock option granted on March 31, 2025 for 50,000 shares included four performance-based vesting tranches. One milestone was achieved, vesting 12,500 shares effective 08/20/2025. The reporting entry shows an option exercise right with an $8.58 conversion price and 12,500 underlying common shares designated as direct ownership following the transaction. The Form 4 was signed 08/22/2025 by Ms. Boenisch and discloses the triggering performance milestone as publication of specified preclinical data.

Christopher U. Missling, President, CEO and Director of Anavex Life Sciences Corp. (AVXL), reported the vesting and acquisition of 125,000 option shares. The Form 4 shows that on 08/20/2025 Mr. Missling acquired 125,000 stock options by exercise of a previously granted option with an $8.58 exercise price. The exercised option became vested following satisfaction of a performance milestone tied to publication of preclinical blarcamesine prevention AD data.

The underlying option was part of a larger grant made on 03/31/2025 for 500,000 options that vest in four equal tranches based on performance milestones; this transaction reflects one tranche vesting. The Form 4 is signed by Mr. Missling on 08/22/2025.

Anavex Life Sciences (AVXL) reported continued clinical progress alongside ongoing operating losses. The company held $101.164 million in cash and cash equivalents at June 30, 2025 and management believes current working capital is sufficient to meet requirements beyond the next 12 months. For the nine months ended June 30, 2025 the company reported a net loss of $36.55 million and used $30.44 million of cash in operations, increasing the accumulated deficit to $372.6 million. Clinical highlights include statistically significant results from its Phase 2b/3 ANAVEX4 2-73 trial in early Alzheimers disease (ADAS-Cog13 and CDR-SB improvements, with dose-group comparisons reported) and an MAA for blarcamesine accepted by the EMA for scientific review. Subsequent to period end the company entered a $150 million at-the-market Sales Agreement with TD Securities, providing an additional capital-raising vehicle. The company disclosed a $1.0 million Michael J. Fox Foundation research grant and noted tax incentive receivables subject to potential ATO review.